Johnson & Johnson reports phase 2 data for nipocalimab in Sjögren’s disease
Johnson & Johnson has released phase 2 clinical trial data indicating that its drug nipocalimab led to increased saliva production in patients with Sjögren’s disease.
Johnson & Johnson presented new phase 2 clinical data on the efficacy of nipocalimab at the ACR 2026 conference. The study results indicate that the treatment contributed to a 50% increase in saliva production among participants diagnosed with Sjögren’s disease, a chronic autoimmune condition.
Alongside the clinical efficacy findings, the company released qualitative data identifying the primary symptoms that patients prioritize for improvement. Participants cited mouth dryness as their most significant concern, followed by eye dryness, persistent fatigue, and joint pain. These findings are intended to align future drug development goals with specific patient-reported outcomes.
Sjögren’s disease remains a challenging condition to treat, with limited therapeutic options currently available for systemic symptom management. Johnson & Johnson is positioning nipocalimab as a potential intervention to address both the objective markers of the disease and the symptomatic burden faced by patients. Further clinical development will continue to evaluate the long-term safety and efficacy of the treatment.